Analyst Thomas Shrader from BTIG maintained a Buy rating on Coya Therapeutics, Inc. and keeping the price target at $15.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Thomas Shrader’s rating is based on the promising developments in Coya Therapeutics’ clinical trials, particularly with their COYA-302 treatment. The expansion of the open-label study for FTD patients, which showed cognitive stability in a cohort that typically experiences decline, is a significant positive indicator. This stability in cognitive function among FTD patients is noteworthy, as untreated patients usually show a decline. The company’s efforts to increase the cohort size and the absence of safety issues further de-risk the treatment.
Additionally, the initiation of a key Phase 2 trial for COYA-302 in ALS, which has shown potential to halt disease progression, adds to the positive outlook. The trial’s design and the FDA’s acceptance of the treatment as a new therapeutic, rather than just a combination of existing biosimilars, suggest strong regulatory support. These factors, combined with the potential for COYA-302 to be part of a registrational package, underpin Shrader’s Buy rating for Coya Therapeutics.
In another report released on September 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.